BeOne Medicines (ONC) Debt to Equity (2016 - 2025)
Historic Debt to Equity for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $0.4.
- BeOne Medicines' Debt to Equity rose 3028.46% to $0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.4, marking a year-over-year increase of 3028.46%. This contributed to the annual value of $0.31 for FY2024, which is 2197.44% up from last year.
- BeOne Medicines' Debt to Equity amounted to $0.4 in Q3 2025, which was up 3028.46% from $0.25 recorded in Q2 2025.
- In the past 5 years, BeOne Medicines' Debt to Equity ranged from a high of $0.4 in Q3 2025 and a low of $0.1 during Q4 2021
- For the 5-year period, BeOne Medicines' Debt to Equity averaged around $0.21, with its median value being $0.17 (2021).
- In the last 5 years, BeOne Medicines' Debt to Equity soared by 39227.03% in 2021 and then plummeted by 3762.14% in 2022.
- BeOne Medicines' Debt to Equity (Quarter) stood at $0.1 in 2021, then increased by 12.65% to $0.12 in 2022, then surged by 116.54% to $0.25 in 2023, then rose by 21.97% to $0.31 in 2024, then soared by 30.48% to $0.4 in 2025.
- Its Debt to Equity stands at $0.4 for Q3 2025, versus $0.25 for Q2 2025 and $0.26 for Q1 2025.